Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

LYNDRA THERAPEUTICS — Lobbying — Receipts Report

LD-2 disclosure · 4th Quarter - Report

LYNDRA THERAPEUTICS

via BGR GOVERNMENT AFFAIRS

4th Quarter (Oct 1 - Dec 31) · 2021Posted Jan 20, 2022Filing document ↗LDA record ↗

Income$60Kfee reported

Client

Name: LYNDRA THERAPEUTICS
Description: Developer of therapeutic medicine
Location: Massachusetts · United States of America

Registrant

Firm: BGR GOVERNMENT AFFAIRS
Description: Lobbying firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Provide strategic guidance and support to advance the utilization of, and investment in, the company's platform and products, and advise the client on legislative, regulatory and potential government partnerships.
LobbyistsROBERT WOOD · BRENT ALAN DEL MONTE · JOHN STONE · DANIEL FARMER · ms REMY LEIGH BRIM MASON
Covered position (ROBERT WOOD): See prior filing
Covered position (BRENT ALAN DEL MONTE): See prior filing
Covered position (JOHN STONE): See prior filing
Covered position (DANIEL FARMER): See prior filing
Covered position (ms REMY LEIGH BRIM MASON): See prior filing
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.